EU authorises Celltrion’s adalimumab biosimilar Yuflyma
Yuflyma is approved across 13 indications for the treatment of multiple chronic inflammatory diseases
Read More
Tag: adalimumab
Takeda’s Entyvio bests AbbVie’s Humira in ulcerative colitis trial
Takeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used biologics for the disease.
Read More
NHS set to save record £300 million on highest drug spend
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
Read More
Amgen begins rolling out Humira biosimilar in the EU
Amgen has begun launching Amgevita, the first biosimilar of AbbVie’s anti-inflammatory blockbuster Humira to win approval in Europe, across the region.
Read More
Novartis’ Aimovig leads CHMP recommendations
The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed nine medicines for approval at its May meeting, including Novartis’ Aimovig, the first human monoclonal antibody for migraine prevention.
Read More
Biogen, Samsung Bioepis and Abbvie settle patent dispute
Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.
Read More
Boehringer bags first biosimilar approval in the EU
Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Read More
Boehringer’s Humira biosimilar wins US green light
US regulators have approved Boehringer Ingelheim’s Cyltezo, a biosimilar to AbbVie’s Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases.
Read More
Final NHS nod for Allergan’s Ozurdex, AbbVie’s Humira in uveitis
Cost regulators for NHS treatments in England and Wales have deemed AbbVie’s Humira and Allergan’s Ozurdex clinically and cost effective for treating adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids.
Read More
NICE backs Humira, Enbrel and Stelara for plaque psoriasis in children
AbbVie’s Humira, Pfizer’s Enbrel, and Janssen’s Stelara are being recommended as options for treating plaque psoriasis in children and young people on the NHS.
Read More
EMA advisors back eight medicines for approval
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More
NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis
Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss.
Read More
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
